Nehls et al (2008) recently observed that adenocarcinoma of extrahepatic bile ducts, including Klatskin's tumours of the liver hilus, seems to have a better prognosis and response to chemotherapy than does intrahepatic cholangiocarcinoma. Furthermore, a differential expression of molecular targets such as HER-2 has been shown recently in intrahepatic and extrahepatic BDC (Yoshikawa et al, 2008). The gene discussed is ERBB2; the disease is extrahepatic bile duct adenocarcinoma.